Navigation Links
InterMune to Release Second Quarter Financial Results on August 4
Date:7/28/2011

BRISBANE, Calif., July 28, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that it will release its second quarter 2011 financial results on Thursday, August 4, 2011. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day to discuss business highlights and financial results for the second quarter and first six months of 2011.

To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 80082950.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80082950.  

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases.  In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
2. InterMune to Webcast 2011 Analyst Day Presentations
3. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
4. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
5. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
6. InterMune to Release First Quarter Financial Results on April 28
7. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
8. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
9. InterMune to Release Third Quarter Financial Results on October 28
10. InterMune Sells Danoprevir Rights to Roche for $175 Million
11. InterMune to Present at 2010 Citi Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Antonio, TX (PRWEB) , ... February 23, 2017 ... ... Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, the ... indicated for adults at home or in healthcare facilities during periods of rest. ...
(Date:2/23/2017)... ... 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) a ... Research . GGI's mission is to advance global health and highlight the greater good ... honor of each clinical trial volunteer. The vision of GGI is to serve as ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one ... been named Fellows of the Society this year, the Fellows Committee has announced. ... fields of optics, photonics, and imaging as well as their service to the ...
(Date:2/22/2017)... 2017  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Annual Biocom Global Life Science Partnering Conference.  The presentation ... at the Torrey Pines Lodge, in San Diego.  ... Biocom who have chosen our company, amongst numerous others, ... investors, and clinical researchers," said Mr. Chen. "In contrast ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/25/2017)... 2017 The Elements of Enterprise Information Security ... comprised of a comprehensive set of business processes ... digital identities and providing a secured and documented ... significant number of programs opted by enterprises to ... optimizing processes and changing policies. However, there are ...
Breaking Biology News(10 mins):